Cold Spring Harbor Laboratory, NCI-designated Cancer Center, 1 Bungtown Rd., Cold Spring Harbor, NY 11724, United States; University of California San Diego, Department of Surgery, NCI-designated Comprehensive Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92093-0987, United States.
Cold Spring Harbor Laboratory, NCI-designated Cancer Center, 1 Bungtown Rd., Cold Spring Harbor, NY 11724, United States.
Curr Opin Genet Dev. 2019 Feb;54:7-11. doi: 10.1016/j.gde.2019.02.003. Epub 2019 Mar 4.
Despite recent advances in the treatment of cancer, pancreatic ductal adenocarcinoma (PDAC) still retains the worst survival rate of common malignancies. Late diagnosis and lack of curative therapeutic options are the most pressing clinical problems for this disease. Therefore, there is a need for patient models and biomarkers that can be applied in the clinic to identify the most effective therapy for a patient. Pancreatic ductal organoids are ex-vivo models of PDAC that can be established from very small biopsies, enabling the study of localized, advanced, and metastatic patients. Organoids models have been applied to pancreatic cancer research and offer a promising platform for precision medicine approaches.
尽管癌症治疗在最近取得了进展，但胰腺导管腺癌（PDAC）的存活率仍然是常见恶性肿瘤中最差的。晚期诊断和缺乏有效的治疗选择是该疾病最紧迫的临床问题。因此，需要能够应用于临床的患者模型和生物标志物，以确定对患者最有效的治疗方法。胰腺导管类器官是 PDAC 的体外模型，可以从小活检中建立，从而能够研究局部、晚期和转移性患者。类器官模型已应用于胰腺癌研究，并为精准医学方法提供了有前途的平台。
